Chronicle Journal: Finance

Biogen stock plunge shows 'investment model in drug development is all wrong,' says former Aetna CEO

Former Aetna Chairman and CEO Mark Bertolini says investors currently are trading "on a basis that says, 'does this drug work today? Did this trial pass today?''"
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.